Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.71 |
| ▸ | NPC1 | O15118 | 1/20 | 0.71 |
| ▸ | RAB9A | P51151 | 1/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.71 |
| ▸ | MAOB | P27338 | 3/20 | 0.58 |
| ▸ | MIF | P14174 | 4/20 | 0.57 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.56 |
| ▸ | ACHE | P22303 | 4/20 | 0.55 |
| ▸ | BCHE | P06276 | 2/20 | 0.55 |
| ▸ | CES2 | O00748 | 2/20 | 0.54 |
| ▸ | MAOA | P21397 | 1/20 | 0.54 |
| ▸ | BACE1 | P56817 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12667768 | 0.83 | NPC1 (1.00) | MEN1NPC1RAB9AKMT2AMAOB | |
| SCHEMBL7787097 | 0.81 | MAOB (0.87) | NPC1RAB9AMAOBMIFCYP19A1 | |
| SCHEMBL30667154 | 0.81 | MAOB (0.87) | NPC1RAB9AMAOBMIFCYP19A1 | |
| SCHEMBL7787095 | 0.81 | MAOB (0.87) | NPC1RAB9AMAOBMIFCYP19A1 | |
| SCHEMBL6291799 | 0.80 | MIF (0.76) | MEN1NPC1RAB9AKMT2AMAOB | |
| SCHEMBL19499513 | 0.80 | MIF (0.76) | MEN1NPC1RAB9AKMT2AMAOB | |
| SCHEMBL8465279 | 0.80 | MAOB (0.68) | MEN1NPC1RAB9AKMT2AMAOB | |
| SCHEMBL8465276 | 0.80 | MAOB (0.68) | MEN1NPC1RAB9AKMT2AMAOB | |
| SCHEMBL29038294 | 0.78 | CES2 (0.80) | MAOBMIFCYP19A1ACHEBCHE | |
| SCHEMBL29038289 | 0.78 | CES2 (0.80) | MAOBMIFCYP19A1ACHEBCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6846817-B2 | Nicotine receptor ligands | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2005-01-25 | — | — | US | disclosed |
| US-20030027810-A1 | Nicotine receptor ligands | REGENTS OF THE UNIVERSITY OF MINNESOTA | 2003-02-06 | — | — | US | disclosed |
| WO-2000073269-A2 | NICOTINE RECEPTOR LIGANDS | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2000-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030027810-A1 | Nicotine receptor ligands | CHRNA1, CHRNB1, CHRNA9 | MEN1 2948/4885NPC1 1319/4885RAB9A 1075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.